Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index
Massimo Breccia, Giuseppina Loglisci, Adriano Salaroli, et al.
Leukemia Research (2012) Vol. 36, Iss. 4, pp. e66-e67
Closed Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia
Javid J. Moslehi, Michael W. Deininger
Journal of Clinical Oncology (2015) Vol. 33, Iss. 35, pp. 4210-4218
Open Access | Times Cited: 405
Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Lauren E. Caldemeyer, Michael J. Dugan, John Edwards, et al.
Current Hematologic Malignancy Reports (2016) Vol. 11, Iss. 2, pp. 71-79
Closed Access | Times Cited: 139
Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing
Bruno C. Medeiros, Jennifer D. Possick, Michael G. Fradley
Blood Reviews (2018) Vol. 32, Iss. 4, pp. 289-299
Open Access | Times Cited: 76
Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?
Alessandra Iurlo, Emanuela Orsi, Daniele Cattaneo, et al.
Oncotarget (2015) Vol. 6, Iss. 32, pp. 33944-33951
Open Access | Times Cited: 61
Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia
Delphine Réa
Annals of Hematology (2015) Vol. 94, Iss. S2, pp. 149-158
Closed Access | Times Cited: 59
Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy
Mary Barber, Michael J. Mauro, Javid J. Moslehi
Hematology (2017) Vol. 2017, Iss. 1, pp. 110-114
Open Access | Times Cited: 51
How tyrosine kinase inhibitors impair metabolism and endocrine system function: A systematic updated review
Massimo Breccia, Matteo Molica, Giuliana Alimena
Leukemia Research (2014) Vol. 38, Iss. 12, pp. 1392-1398
Closed Access | Times Cited: 49
Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin
Yoshikiyo Ito, Toshihiro Miyamoto, Yong Chong, et al.
International Journal of Hematology (2012) Vol. 97, Iss. 1, pp. 135-138
Closed Access | Times Cited: 41
Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US
Meg Franklin, Leah Burns, Samuel Perez, et al.
Current Medical Research and Opinion (2017) Vol. 34, Iss. 2, pp. 353-360
Closed Access | Times Cited: 30
Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events
Benedito A. Carneiro, Jason Kaplan, Francis J. Giles
Expert Review of Hematology (2015) Vol. 8, Iss. 4, pp. 457-479
Closed Access | Times Cited: 26
BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
Hélène Haguet, Jonathan Douxfils, C Chatelain, et al.
TH Open (2018) Vol. 02, Iss. 01, pp. e68-e88
Open Access | Times Cited: 26
Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitors
P. Buffier, Benjamin Bouillet, Sarra Smati, et al.
Annales d Endocrinologie (2018) Vol. 79, Iss. 5, pp. 574-582
Closed Access | Times Cited: 26
Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR-ABL inhibitor use by using an adverse drug event reporting database
Naoto Okada, Takahiro Niimura, Yoshito Zamami, et al.
Cancer Medicine (2018) Vol. 8, Iss. 1, pp. 174-181
Open Access | Times Cited: 21
Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia.
Javier Pinilla‐Ibarz, Kendra Sweet, Josephine Emole, et al.
PubMed (2015) Vol. 35, Iss. 12, pp. 6355-64
Closed Access | Times Cited: 20
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
Javier Pinilla‐Ibarz, Josephine Emole, Taiwo Talabi
Biologics (2016), pp. 23-23
Open Access | Times Cited: 17
Proposal for a tailored stratification at baseline and monitoring of cardiovascular effects during follow-up in chronic phase chronic myeloid leukemia patients treated with nilotinib frontline
Massimo Breccia, Eleonora Arboscello, Andrea Bellodi, et al.
Critical Reviews in Oncology/Hematology (2016) Vol. 107, pp. 190-198
Closed Access | Times Cited: 15
Lifelong TKI therapy: how to manage cardiovascular and other risks
Michael J. Mauro
Hematology (2021) Vol. 2021, Iss. 1, pp. 113-121
Open Access | Times Cited: 11
Blockage of endoplasmic reticulum stress attenuates nilotinib-induced cardiotoxicity by inhibition of the Akt-GSK3β-Nox4 signaling
Qinghui Yang, Liang Wen, Zenghui Meng, et al.
European Journal of Pharmacology (2018) Vol. 822, pp. 85-94
Closed Access | Times Cited: 11
Impact of tyrosine kinase inhibitors on glucose control and insulin regulation in patients with chronic myeloid leukemia
Lando Janssen, Maria T. E. Hopman, Greetje J. A. Swaans, et al.
AJP Endocrinology and Metabolism (2023) Vol. 324, Iss. 3, pp. E209-E216
Closed Access | Times Cited: 3
Comparative Pharmacology of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
José Ramón Azanza Perea, Belén Rada, Nieves Gandía
International Journal of Clinical Pharmacology & Pharmacotherapy (2018) Vol. 3, Iss. 1
Open Access | Times Cited: 8
Genetic risk of prediabetes and diabetes development in chronic myeloid leukemia patients treated with nilotinib
Bruno Martino, Corrado Mammì, Claudia Labate, et al.
Experimental Hematology (2017) Vol. 55, pp. 71-75
Open Access | Times Cited: 4
Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies
Tarsheen Sethi, Basak Basdag, Nirmanmoh Bhatia, et al.
Current Hematologic Malignancy Reports (2017) Vol. 12, Iss. 3, pp. 257-267
Closed Access | Times Cited: 3
Second-generation TKIs: which and when?
Giuseppe Saglio
Leukemia Supplements (2012) Vol. 1, Iss. S2, pp. S40-S42
Open Access | Times Cited: 1
Pharmacology and pharmacovigilance of protein kinase inhibitors
Charles Khouri, Julien Mahé, Laura Caquelin, et al.
Therapies (2021) Vol. 77, Iss. 2, pp. 207-217
Open Access | Times Cited: 2
Management of Adverse Events Associated with ATP-Competitive BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Delphine Réa
Hematologic malignancies (2016), pp. 71-87
Closed Access
Page 1 - Next Page

Scroll to top